 | • レポートコード：MRC2303I0169 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の遅発性ジスキネジア治療市場規模が、予測期間中（2022年-2027年）に年平均4.2%で成長すると予測しています。本書では遅発性ジスキネジア治療の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疾患別（運動緩慢、多動症）分析、医薬品種類別（ドーパミン枯渇薬、VMAT2阻害剤、GABA受容体作動薬、抗コリン薬トリヘキシフェニジル）分析、エンドユーザー別（病院、臨床、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、南米、中東・アフリカ、アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、その他）分析、競争状況、市場機会・将来の動向など、以下の構成でまとめております。また、Teva Pharmaceutical Industries Ltd、Neurocrine Biosciences, Inc、Sun Pharmaceutical Industries Ltd、SteriMax Inc.、Adamas Pharmaceuticals, Inc、Sanis、AbbVie Inc.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の遅発性ジスキネジア治療市場規模：疾患別 - 運動緩慢の市場規模 - 多動症の市場規模 ・世界の遅発性ジスキネジア治療市場規模：医薬品種類別 - ドーパミン枯渇薬の市場規模 - VMAT2阻害剤の市場規模 - GABA受容体作動薬の市場規模 - 抗コリン薬トリヘキシフェニジルの市場規模 ・世界の遅発性ジスキネジア治療市場規模：エンドユーザー別 - 病院における市場規模 - 臨床における市場規模 - その他エンドユーザーにおける市場規模 ・世界の遅発性ジスキネジア治療市場規模：地域別 - 北米の遅発性ジスキネジア治療市場規模 アメリカの遅発性ジスキネジア治療市場規模 カナダの遅発性ジスキネジア治療市場規模 メキシコの遅発性ジスキネジア治療市場規模 … - ヨーロッパの遅発性ジスキネジア治療市場規模 ドイツの遅発性ジスキネジア治療市場規模 イギリスの遅発性ジスキネジア治療市場規模 フランスの遅発性ジスキネジア治療市場規模 … - アジア太平洋の遅発性ジスキネジア治療市場規模 中国の遅発性ジスキネジア治療市場規模 インドの遅発性ジスキネジア治療市場規模 日本の遅発性ジスキネジア治療市場規模 … - その他地域の遅発性ジスキネジア治療市場規模 ・競争状況 ・市場機会・将来の動向 |
The Tardive Dyskinesia Treatment Market is expected to register a CAGR of 4.2% during the forecast period (2022-2027).
COVID-19 has impacted the patient’s access to healthcare facilities as the pandemic has forced the patients to wait for life-saving diagnostics as well as treatment procedures. To slow the spread of the virus, many hospitals have reduced or postponed non-emergency services, like screenings and diagnostic scans. According to the article published in Verywellhealth in October 2021, titled “What to Know About Tardive Dyskinesia and COVID-19,” mental health disorders showed an association between the presence of any mental illness and an increased need for hospitalization or dying from COVID-19.
This is attributed to the growing number of Schizophrenia Patients and rising incidences of neurological disorders. With the long-term use of antipsychotic drugs by schizophrenia patients, the chances of patients suffering from tardive dyskinesia are high. Thus high risk is associated with a growing number of antipsychotic drugs leading to promoting the growth of the overall market. For instance, as per the World Health Organization Report in January 2022, Schizophrenia affects about 24 million individuals globally or 0.32%. Adults had a rate of 1 in 222 persons (0.45%).
Furthermore, the global prevalence of Parkinson’s disease is estimated to be approximately 6.1 million globally, and the prevalence increases with age, reaching 1% to 3% in the population over 65 years of age, as per the research article “Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future” published in February 2022. In addition, the data updated by World Health Organization (WHO) in October 2021 shows that by 2030, 1 in 6 people in the world will be aged 60 years or over. Thus, rising in the prevalence of Alzheimer’s disease is expected to rise in the pool population for tardive dyskinesia, thereby increasing the need for treatment, likely to boost the market.
Additionally, Also, the increasing prevalence of epilepsy in Mexico is also one of the factors driving the growth of the market studied. According to Anales Médicos de la Asociación Médica del Centro Médico ABC, in 2020, Epilepsy has a higher prevalence in developing countries and in Mexico. Prevalence of epilepsy in Mexico was reported with rates of 3.9 to 42.2 per 1,000 inhabitants. Thus increasing the prevalence of neurological diseases tardive dyskinesia population is expected to increase, thereby boosting the market studied.
However, side effects of drugs lack awareness about the disorder, and many undiagnosed cases may restrain the market to a certain extent.
Tardive Dyskinesia Treatment Market Trends
VMAT Inhibitor is Expected to Grow Faster Over the Forecast Period
The vesicular monoamine transporter type 2 (VMAT2) inhibitors are agents that cause a depletion of neuroactive peptides such as dopamine in nerve terminals and are used to treat chorea due to neurodegenerative diseases (such as Huntington chorea) or dyskinesias due to neuroleptic medications (tardive dyskinesia).
VMAT is expected to witness healthy growth in the future attributed to a growing number of neurological disorders and growing antipsychotic prescriptions. the global prevalence of Parkinson’s disease is estimated to be approximately 6.1 million globally, and the prevalence increases with age, reaching 1% to 3% in the population over 65 years of age, as per the research article “Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future” published in February 2022. In addition, the data updated by World Health Organization (WHO) in October 2021 shows that by 2030, 1 in 6 people in the world will be aged 60 years or over. Tardive dyskinesia is associated with Parkinson’s therapy, and it is expected that the prevalence of Parkinson’s disease will rise over the forecast period, resulting in increased demand for the treatment option, and boosting segment growth.
Several product approvals in VMAT inhibitors are promoting the growth of the market. For instance, in May 2022, Neurocrine Biosciences presented new INGREZZA (valbenazine) data on tardive dyskinesia improvement and stability of psychiatric symptoms at the American Psychiatric Association Annual Meeting 2022. Such developments are expected to drive the tardive dyskinesia treatment market.
Several product approvals in VMAT inhibitors are promoting the growth of the market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a significant market share in the global tardive dyskinesia treatment market due to the increasing aging population, high prevalence of schizophrenia, increasing awareness, increasing healthcare expenditure, and the presence of well-established healthcare infrastructure. As the growing aging population will be leading to many diseases related to neurological for which this population has to take antipsychiatric drugs. Thus these populations are more prone to develop these diseases. According to the National Alliance on Mental Health in May 2021, the prevalence of schizophrenia in the United States is in the range of 0.25% to 0.64%, or 1.5 million people per year.
Additionally, the data provided in the article “The Financial Burden from Parkinson’s Exacts a High Cost” published in September 2021 shows that in the United States, an estimated 1 million people have Parkinson’s disease, and more people are diagnosed with it every year, among which the prevalence is more among people of age 65 years or older. As per the source above, the prevalence of PD also has increased among people younger than 65. Additionally, the data updated by Parkinson Canada’s National Roundtable Report in March 2022 shows that in Canada, more than 100,000 people have PD, and this number will grow in the coming days reaching 50 new diagnoses every day within 10 years. Thus, the high burden of the disease among the target population of countries across North America is anticipated to create demand for the development of drugs for treatment. Thereby, driving the market growth.
Moreover, targeted patient pools such as populations treated with schizophrenia and bipolar disorder in this region are also associated with this disorder, hence promoting the growth of the tardive dyskinesia treatment market in this region.
Tardive Dyskinesia Treatment Market Competitor Analysis
The Tardive Dyskinesia Treatment Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Teva Pharmaceutical Industries Ltd, Neurocrine Biosciences, Inc, Sun Pharmaceutical Industries Ltd, SteriMax Inc., Lannett Co Inc, Sanis, and Allergan.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Neurological Disorder
4.2.2 Growing Antipsychotic Prescriptions
4.2.3 Rising Schizophrenia Patients
4.3 Market Restraints
4.3.1 Side Effects of Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value in USD Million)
5.1 By Disorder
5.1.1 Bradykinesia
5.1.2 Hyperkinesia
5.2 By Drug Class
5.2.1 Dopamine-Depleting Medications
5.2.2 VMAT2 Inhibitors
5.2.3 GABA Receptor Agonist Medications
5.2.4 Anticholinergic Medications Trihexyphenidyl
5.3 By End User
5.3.1 Hospitals
5.3.2 Clinical
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Rest of the World
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Teva Pharmaceutical Industries Ltd
6.1.2 Neurocrine Biosciences, Inc
6.1.3 Sun Pharmaceutical Industries Ltd
6.1.4 SteriMax Inc.
6.1.5 Adamas Pharmaceuticals, Inc
6.1.6 Sanis
6.1.7 AbbVie Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS